Agenus inc. class action reminder - agen stockholders with large losses they should contact shareholder rights law firm robbins llp for information about the agenus inc. class action lawsuit

San diego, sept. 30, 2024 (globe newswire) -- robbins llp reminds investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired agenus inc. (nasdaq: agen) securities between january 23, 2023 and july 17, 2024. agenus is a clinical-stage biotechnology company that discovers and develops immuno-oncology (“i-o”) products in the u.s. and internationally. among other product candidates, the company is developing balstilimab, an anti-pd-1 antagonist that has completed a phase 2 clinical trial to treat second line cervical cancer; and botensilimab (agen1181), an antigen 4 (ctla-4) blocking antibody that is in a phase 2 clinical trial for the treatment of pancreatic cancer and melanoma.
AGEN Ratings Summary
AGEN Quant Ranking